# Assembly Biosciences Inc. (ASMB) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $19.92, market value $406 million.

## Valuation
- **P/E (trailing): 19.2×**. Assembly Biosciences Inc. trades at 19.2× trailing earnings. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 5.4×**. Each dollar of revenue is priced at 5.4×.
- **Price / book: 1.3×**. The shares trade at 1.3× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -9.5%** (5-yr avg -49.0%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.
- **Earnings yield: 5.2%**. The inverse of the P/E: 5.2% of the price is earned each year.

## Profitability
- **Operating margin: -11.8%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -8.5%**. The company reported a net loss over the last twelve months.
- **Return on equity: -3.0%**. Return on equity is negative because earnings are negative.
- **Return on assets: -0.0%**. Each dollar of assets produces -0.0% of profit.

## Growth
- **Revenue growth (1 yr): 153.5%** (5-yr -1.8%/yr). Revenue grew 153.5% over the last year, against -1.8% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 91.8%**. Earnings per share rose 91.8%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 5.22** (quick 5.22). Current assets cover the next year's liabilities 5.22 times.
- **Altman Z-score: 6.99**. A Z-score of 6.99 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Assembly Biosciences Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (5 analysts). 5 analysts cover Assembly Biosciences Inc.; the consensus is strong_buy, with an average price target of $52.00 (+161% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -37.2%** (YTD -42.6%, 3-mo -23.1%). The shares are down 37.2% over twelve months including dividends.
- **From 52-week high: -49.8%** (3.5% above the low). Trading 50% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 33**. An RSI of 33 is neutral.
- **Beta (1 yr): 1.40** (volatility 59%). Beta of 1.40 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ASMB · Page: https://foliofundamentals.com/stocks/asmb

Not investment advice.